LVAD versus standard heart failure medicines in advanced patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial compares an LVAD device (a pump placed in the chest) plus medicines versus medicines alone for people with advanced, end-stage heart failure. It aims to see which approach works better to help patients live and stay out of the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have advanced “end-stage” heart failure despite best medicines, with low heart pumping ability (such as low ejection fraction) and severe symptoms (NYHA class III–IV)
- Have taken the usual heart failure medicines at the highest tolerated doses for at least 45 days (including certain blood-pressure medicines, mineralocorticoid blockers, and SGLT2 inhibitors)
- If you need them, have had a pacemaker/defibrillator setup (cardiac resynchronization therapy and/or implantable cardioverter-defibrillator) for at least 45 days
- Not be dependent on IV heart-strengthening medicines (inotropes) or have had a heart pump device in the last 30 days
- Have no major exclusions like serious uncontrolled infection, inability to take blood thinners, or severe organ damage that would limit survival
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well people with advanced heart failure do over the long term after getting a left-ventricular assist device (LVAD). Researchers will check blood and heart tissue samples to learn more about recovery and outcomes.
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
This trial is studying a non-surgical (conservative) treatment approach for people being considered for a left ventricular assist device (LVAD). It may help some patients who are too sick or unable to tolerate standard heart failure medicines, but it will only match people with specific heart function and health-test results.
This trial tests a new left-ventricular assist device (LVAD) called BrioVAD for people with advanced heart failure who are not getting enough benefit from medicines. If you qualify, the device is implanted to help your heart pump blood.
This trial tests a new heart pump (BrioVAD) for people with very advanced heart failure. It aims to help those who are not getting better with standard treatments or who need extra support like IV medicines or a balloon pump.
This trial tests a new left ventricular assist device (LVAD) for people with advanced heart failure who are not responding to standard treatments and are eligible for a heart transplant. The pump helps the heart circulate blood.
Hear when a new End-stage Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.